Pharmaceuticals Global News & Press Release Distribution

Pharmaceuticals

All
APAC

FDA Grants Orphan Drug Designation (ODD) Status to Zymedi's ZMA001 for Pulmonary Arterial Hypertension

INCHEON, South Korea, July 30, 2024 /PRNewswire/ -- Zymedi (CEO Sunghoon Kim) announced that its first-in-class antibody treatment ZMA001, currently in development for pulmonary arterial hypertension (PAH), has been designated as an Orphan Drug by the U.S. Food and Drug Administration (FDA). Pul...

2024-07-31 08:00 1646

Porton Advanced and Geneseed Biotech Enter into Strategic Collaboration to Focus on Advancing circRNA Innovative Therapeutics

SUZHOU, China, July 30, 2024 /PRNewswire/ -- On July 29, 2024, Porton Advanced Solutions ("Porton Advanced") announced that it had reached a strategic cooperation with Guangzhou Geneseed Biotech Co., Ltd ("Geneseed Biotech"). Both sides will combine their respective strengths in the field of gene...

2024-07-30 22:00 2387

Porton Advanced and Geneseed Biotech Enter into Strategic Collaboration to Focus on Advancing circRNA Innovative Therapeutics

Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis

SEONGNAM, South Korea, July 29, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based inSouth Korea developing novel drugs for fibrosis and cancer, today announced that patient participant enrollment has been completed in the Phase 2 clinical study of BBT-...

2024-07-30 06:00 1532

Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-in-Class PRS Inhibitor, Bersiporocin

SEOUL, South Korea, July 29, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOsChang-Jae Lee and Seongsoo Park) announced a significant milestone in the development of 'Bersiporocin (DWN12088)', a first-in-class PRS inhibitor for idiopathic pulmonary fibrosis (IPF), has taken a significant ste...

2024-07-29 20:00 1794

Akeso's sBLA for Ivonescimab in 1L Treatment of PD-L1 Positive NSCLC Accepted by NMPA

HONG KONG, July 29, 2024 /PRNewswire/ -- Akeso (9926.HK) is delighted to announce that the supplemental biologics license application (sBLA) for its independently developed, world's first-in-class PD-1/VEGF bispecific antibody drug, 依达方® (generic name: ivonescimab Injection), as a monotherapy for...

2024-07-29 17:26 1743

111 to Announce Second Quarter 2024 Unaudited Financial Results on August 29, 2024 - Conference Call to Follow

SHANGHAI, July 29, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced that it will repor...

2024-07-29 13:00 1628

Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder

PRINCETON, N.J., July 28, 2024 /PRNewswire/ -- Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sales of innovative medications, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's ERZOFRI® (pa...

2024-07-28 21:48 3006

ReviR Therapeutics Raises $30 Million Series A Financing to Advance its Proprietary Oral Genetic Medicines for Multiple CNS Disorders

BRISBANE, Calif., July 26, 2024 /PRNewswire/ -- ReviR Therapeutics, an AI-enabled biotechnology company focused on developing small molecule RNA modulators for neurogenetic diseases, announced today that it has successfully completed a$30 million Series A financing, bringing the total raised so f...

2024-07-26 21:00 3146

HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update

* HanAll reports strong financial performance with second quarter total revenue of31.6 billion KRW, driven by the strong sales from the key products. * HanAll expands collaboration with Turn Biotechnologies through an exclusive licensing agreement for Epigenetic Reprogramming of Aging (ERATM) ...

2024-07-26 19:00 4526

Sanyou Bio Congratulates Eluminex Biosciences and Foreseen Biotechnology on Major Breakthroughs in Innovative Drug Project

SHANGHAI, July 26, 2024 /PRNewswire/ -- On July 15, Eluminex Biosciences announced that their tri-specific fusion antibody drug, EB-105, has administered its first dose to a diabetic macular edema patient inthe United States. This clinical trial, known as LOTUS, is an open-label, multicenter, si...

2024-07-26 18:00 3857

Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China , July 25, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immuno...

2024-07-26 10:16 1790

Ractigen Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy

SUZHOU, China, July 25, 2024 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to RAG-18, one of the company's lead saRN...

2024-07-25 20:00 1858

IASO Bio Announces NMPA Approval of IND Application for IASO-782 for Treatment of New Indication -- Systemic Lupus Erythematosus (SLE)

SHANGHAI, NANJING, China and SAN JOSE, Calif. , July 25, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, hereby announces thatthe investigation...

2024-07-25 17:46 2063

Full-Life Technologies Announces the Appointment of Edward (Ted) Myles to Its Board of Directors

HEIDELBERG, Germany and GEMBLOUX, Belgium and SHANGHAI, China, July 21, 2024 /PRNewswire/ -- Full-Life Technologies, a fully integrated global radiotherapeutics company, today announcedthe appointment of Ted Myles to Full-Life's Board of Directors. Mr. Myles will serve as chairman of the audit c...

2024-07-22 08:00 1277

Treatment of Type 2 diabetes with Chiglitazar combined with Metformin Approved for listing by the National Medical Products Administration

SHENZHEN, China, July 19, 2024 /PRNewswire/ -- On July 19, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Biosciences") announced that it has received the Drug Registration Certificate approved and issued by the National Medical Products Administration (NMPA) fo...

2024-07-19 22:01 4823

Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, July 18, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...

2024-07-19 07:15 2837

ACROBiosystems Launches GMP Brand Resilient Supply at ISSCR to Accelerate Cell and Gene Therapy Development

NEWARK, Del., July 18, 2024 /PRNewswire/ -- At the recent International Society for Stem Cell Research (ISSCR) Annual Meeting inHamburg, ACROBiosystems announced its new GMP-centered brand, Resilient Supply, with the mission of accelerating the advancement of cell and gene therapy (CGT) developme...

2024-07-19 00:00 2234

Assessment of supply chain risk key to improving medicine access

A four-year research project by INSEAD and five other institutions sheds light on how understandingmedical criticality, supply chain risk and their interactions could help us better address drug shortages. FONTAINEBLEAU, France, SINGAPORE and SAN FRANCISCO, July 18, 2024 /PRNewswire/ -- Drug s...

2024-07-18 23:00 2186

Duoning showcases its comprehensive bioprocess solutions at Interphex Korea 2024

SHANGHAI, July 18, 2024 /PRNewswire/ -- Duoning Biotechnology Group ("Duoning"), a leading one-stop bioprocess solution provider, announced it has attended at Interphex Korea 2024 to showcase its total bioprocess solutions for the preparation of diverse biological products. Interphex 2024 provide...

2024-07-18 20:00 1943

MicuRx Presents Innovative Antibiotic Research Results at the 7th World Bronchiectasis Conference

* MicuRx showcased the latest research progress on their pipeline products, MRX-5 and MRX-8, at the 7th World Bronchiectasis Conference * Three significant study results further support the potential of MRX-5 and MRX-8 in treating Nontuberculous Mycobacteria (NTM) lung disease and Pseudomonas...

2024-07-18 13:19 1292

MicuRx Presents Innovative Antibiotic Research Results at the 7th World Bronchiectasis Conference

1 ... 9 10 111213 14 15 ... 126